Digital Pill System for Alcohol-Related Liver Disease

This trial explores a new digital pill system combined with therapy to help individuals adhere to their medication for alcohol-related liver disease. The treatment, called AcamproSync, tracks medication intake and offers support using cognitive behavioral therapy techniques. The goal is to improve medication adherence and provide personalized assistance for those with alcohol use disorder and liver disease. Individuals receiving treatment for alcohol use disorder and planning to start acamprosate may be suitable candidates for this study. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance treatment strategies for alcohol-related liver disease.

The trial information does not specify if you need to stop taking your current medications. However, since the trial involves starting acamprosate, it's best to discuss your current medications with the trial team to ensure there are no interactions.

Previous studies have shown that acamprosate, the active ingredient in AcamproSync, is generally safe for people with liver problems related to alcohol use. Research indicates that most people tolerate acamprosate well, though some studies suggest it might increase hospital readmissions in patients with severe liver conditions like cirrhosis and alcohol-related hepatitis. The drug is considered safe for people with liver disease because the kidneys process it instead of the liver, reducing the risk of liver-related side effects. However, more research is needed to fully understand its long-term effects. Overall, acamprosate appears safe for many patients.¹²³⁴⁵

Unlike traditional treatments for alcohol-related liver disease, which mainly focus on managing symptoms and slowing disease progression, the AcamproSync system offers a fresh approach by directly measuring medication adherence. This innovative system integrates a digital pill that tracks how consistently patients take acamprosate, a medication that helps reduce alcohol cravings. Additionally, the system provides personalized cognitive-behavioral therapy interventions tailored to each individual's needs, aiming to enhance adherence and promote self-awareness of drinking patterns. Researchers are excited about this treatment because it combines technology with therapy to potentially improve patient outcomes and offer more precise management of alcohol-related liver disease.

Research has shown that acamprosate can reduce the urge to drink alcohol and lower alcohol use, potentially preventing liver disease from worsening. Studies have found that taking medications like acamprosate for at least three months can improve long-term survival for people with alcohol use disorder (AUD). Acamprosate is safe for individuals with liver disease because the kidneys, not the liver, process it. In this trial, participants in the AcamproSync arm will use the Digital Pill System, which helps track medication intake and offers personalized support through cognitive behavioral therapy (CBT). This combination aims to enhance acamprosate's effectiveness by promoting adherence to treatment plans. Meanwhile, participants in the control arm will receive standard treatment.²⁴⁶⁷⁸